Stock 4598 DELTA-FLY PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Delta-Fly Pharma, Inc.

Equities

4598

JP3549370009

Market Closed - Japan Exchange
Other stock markets
 07:00:00 26/06/2024 BST 		5-day change 1st Jan Change
566 JPY +4.24% Intraday chart for Delta-Fly Pharma, Inc. -1.05% -44.24%
04-08 Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax CI
03-11 Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Delta-Fly Pharma Inc.: Mitteilung der Zulassung der Phase I/II-Studie zu DFP-10917 in Kombination mit Venetoclax
Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax
Delta-Fly Pharma Inc.: FDA-Einreichung des Protokolls der Phase I/II-Studie von DFP-10917 in Kombination mit Venetoclax (VTX) bei AML-Patienten, die mit VTX vorbehandelt wurden, umfasste ein Regime
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML
Delta-Fly Pharma Inc.: Einreichung von Abstracts für klinische Phase I-Studie von DFP-14927 für die ASCO-Jahresversammlung 2024
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting
Delta-Fly Pharma Inc.: Bekanntmachung des Beginns einer klinischen Phase-III-Vergleichsstudie mit DFP-14323
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML
Delta-Fly Pharma Inc.: Aktueller Stand der Forschung und Entwicklung von DFP-10917 und DFP-14927, einem neuartigen PEG-Wirkstoffkonjugat für Patienten mit R/R AML
Delta-Fly Pharma Inc.: Zeitplan für die Zwischenanalyse der Phase-3-Studie von DFP-10917 bei rezidivierter/refraktärer akuter myeloischer Leukämie (R/R AML)
Delta-Fly Pharma, Inc. erhält von der US Food and Drug Administration die Orphan Drug Designation für DFP-10917
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4598 Stock
  4. News Delta-Fly Pharma, Inc.
  5. Other languages